File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment outcomes of primary pulmonary lymphoepithelioma-like carcinoma: A series of 22 patients and treatment strategy review

TitleTreatment outcomes of primary pulmonary lymphoepithelioma-like carcinoma: A series of 22 patients and treatment strategy review
Authors
KeywordsEpstein-Barr virus infections
Carcinoma
Lung neoplasms
Non-small-cell lung
Radiotherapy
Survival
Issue Date2013
Citation
Hong Kong Journal of Radiology, 2013, v. 16, n. 4, p. 270-277 How to Cite?
AbstractObjectives: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subgroup of non-small-cell lung cancer. Limited published series suggested that it might be associated with more favourable survival than ordinary non-small-cell lung cancer. We set out to review the treatment outcomes of patients with primary pulmonary LELC treated in our institution since 1994. Methods: All patients with pathologically confirmed primary pulmonary LELC treated between 1994 and 2012 were retrospectively reviewed. Treatment modalities and outcomes- including local control rate, disease-free and overall survival- were analysed. Results: Twenty-two patients with primary pulmonary LELC were identified. Their median follow-up duration was 33 months (range, 1 day to 106 months). Surgery was the mainstay of treatment for patients with stage I to II diseases. Those with advanced non-metastatic disease (n = 5) treated with high-dose radiotherapy (EQD2 60 Gy) with or without platinum-based chemotherapy had a local control rate of 100% after a median follow-up of 68 months. The 5-year progression-free survival (PFS) and overall survival (OS) were 53% and 80%, respectively. Their median PFS and OS had not reached at the time of publication. For patients with stages III and IV disease beyond radical radiotherapy portals, palliative platinum doublets gave a median disease-free survival of 10 months in 12 patients. The 5-year OS of stage /-//, III, and IV patients were 41%, 38%, and 25%, respectively (p = 0.61). Their median OS durations were 58, 30, and 19 months, respectively. Conclusion: Our series echoed prior suggestions that primary pulmonary LELC achieves favourable outcomes. © 2013 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/239755
ISSN
2023 Impact Factor: 0.2
2023 SCImago Journal Rankings: 0.127
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMok, F. S T-
dc.contributor.authorChan, O. S H-
dc.contributor.authorChang, A. T Y-
dc.contributor.authorChan, L. L K-
dc.contributor.authorSoong, I. S.-
dc.contributor.authorNg, W. T.-
dc.contributor.authorCheung, F. Y.-
dc.contributor.authorYeung, R. M W-
dc.date.accessioned2017-04-03T02:41:20Z-
dc.date.available2017-04-03T02:41:20Z-
dc.date.issued2013-
dc.identifier.citationHong Kong Journal of Radiology, 2013, v. 16, n. 4, p. 270-277-
dc.identifier.issn2223-6619-
dc.identifier.urihttp://hdl.handle.net/10722/239755-
dc.description.abstractObjectives: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subgroup of non-small-cell lung cancer. Limited published series suggested that it might be associated with more favourable survival than ordinary non-small-cell lung cancer. We set out to review the treatment outcomes of patients with primary pulmonary LELC treated in our institution since 1994. Methods: All patients with pathologically confirmed primary pulmonary LELC treated between 1994 and 2012 were retrospectively reviewed. Treatment modalities and outcomes- including local control rate, disease-free and overall survival- were analysed. Results: Twenty-two patients with primary pulmonary LELC were identified. Their median follow-up duration was 33 months (range, 1 day to 106 months). Surgery was the mainstay of treatment for patients with stage I to II diseases. Those with advanced non-metastatic disease (n = 5) treated with high-dose radiotherapy (EQD2 60 Gy) with or without platinum-based chemotherapy had a local control rate of 100% after a median follow-up of 68 months. The 5-year progression-free survival (PFS) and overall survival (OS) were 53% and 80%, respectively. Their median PFS and OS had not reached at the time of publication. For patients with stages III and IV disease beyond radical radiotherapy portals, palliative platinum doublets gave a median disease-free survival of 10 months in 12 patients. The 5-year OS of stage /-//, III, and IV patients were 41%, 38%, and 25%, respectively (p = 0.61). Their median OS durations were 58, 30, and 19 months, respectively. Conclusion: Our series echoed prior suggestions that primary pulmonary LELC achieves favourable outcomes. © 2013 Hong Kong College of Radiologists.-
dc.languageeng-
dc.relation.ispartofHong Kong Journal of Radiology-
dc.subjectEpstein-Barr virus infections-
dc.subjectCarcinoma-
dc.subjectLung neoplasms-
dc.subjectNon-small-cell lung-
dc.subjectRadiotherapy-
dc.subjectSurvival-
dc.titleTreatment outcomes of primary pulmonary lymphoepithelioma-like carcinoma: A series of 22 patients and treatment strategy review-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.12809/hkjr1313176-
dc.identifier.scopuseid_2-s2.0-84892700172-
dc.identifier.volume16-
dc.identifier.issue4-
dc.identifier.spage270-
dc.identifier.epage277-
dc.identifier.isiWOS:000417024300005-
dc.identifier.issnl2223-6619-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats